Search

Background: Polyethylene glycol (PEG)-based bowel preparations are effective cleansers but many require high-volume intake. This phase 3, randomized, blinded, multicenter, parallel-group, central reader-assessed study assessed the 1 L PEG NER1006 bowel preparation vs. standard 2 L PEG with ascorbate (2LPEG)., Methods: Patients undergoing colonoscopy were randomized (1:1:1) to receive NER1006, as an evening/morning (N2D) or morning-only (N1D) regimen, or evening/morning 2LPEG. Cleansing was assessed using the Harefield Cleansing Scale (HCS) and the Boston Bowel Preparation Scale (BBPS). Primary end points were overall bowel cleansing success and high-quality cleansing in the right colon. Modified full analysis set (mFAS) and per protocol (PP) analyses were performed. Mean cleansing scores were analyzed post hoc . RESULTS:  Of 849 randomized patients, efficacy was analyzed in the following patient numbers (mFAS/PP): total n = 822/670; N2D n = 275/220; N1D n = 275/218; 2LPEG n = 272/232. mFAS established noninferiority. PP showed superiority for N2D on overall success (97.3 % vs. 92.2 %; P  = 0.014), and for N2D and N1D on right colon high-quality cleansing (N2D 32.3 % vs. 15.9 %, P  < 0.001; N1D 34.4 % vs. 15.9 %, P  < 0.001) vs. 2LPEG. Using HCS, N2D and N1D attained superior segmental high-quality cleansing ( P  ≤ 0.003 per segment). N2D showed superior mean segmental HCS scores ( P  ≤ 0.007 per segment). Both N2D and N1D achieved superior mean overall ( P  < 0.001 and P  = 0.006) and right colon BBPS scores ( P  < 0.001 and P  = 0.013). N2D demonstrated superior right colon polyp detection ( P  = 0.024). Adherence, tolerability, and safety were comparable between treatments., Conclusions: NER1006 is the first low-volume preparation to demonstrate superior colon cleansing efficacy vs. standard 2LPEG with ascorbate, with comparable safety and tolerability. European Clinical Trials Database (EudraCT)2014-002185-78TRIAL REGISTRATION: Multicenter, randomized, parallel group, phase 3 trial 2014-002185-78 at https://eudract.ema.europa.eu/., Competing Interests: Raf Bisschops has received honoraria from Norgine for speaking and Advisory Board attendance. Jonathan Manning has received honoraria from Norgine for speaking and for Investigator Advisory Board attendance. Lucy Clayton and Richard Ng Kwet Shing are employees of Norgine. Marco Antonio Álvarez-González has received honoraria from Norgine for Advisory Board attendance and from Casen-Recordati for speaking and teaching. This study was funded by Norgine Ltd. (Harefield, UK)., (© Georg Thieme Verlag KG Stuttgart · New York.)

In recent years, there is a growing body of evidence that the University of Wisconsin (UW) solution offers many advantages in organ preservation with regard to preservation quality and time. We, therefore, conducted the first European prospective, randomized, clinical trial comparing myocardial performance after preservation with UW and St. Thomas Hospital (ST) solution. Preliminary results indicated superior heart function after preservation with UW solution.